omeprazole and exenatide

omeprazole has been researched along with exenatide in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bahekar, R; Detroja, J; Dhanesha, N; Dhote, V; Gandhi, T; Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, K; Patel, V1
Bahekar, R; Detroja, J; Dhanesha, N; Gandhi, T; Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, K; Patel, V1

Reviews

1 review(s) available for omeprazole and exenatide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

2 other study(ies) available for omeprazole and exenatide

ArticleYear
Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
    Journal of diabetes, 2013, Volume: 5, Issue:2

    Topics: Animals; Anti-Obesity Agents; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Gastrins; Glucagon; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred Strains; Mice, Obese; Obesity; Omeprazole; Peptides; Venoms

2013
Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
    Pharmacological reports : PR, 2013, Volume: 65, Issue:4

    Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Male; Mice; NF-E2-Related Factor 2; Omeprazole; Peptides; Proton Pump Inhibitors; Venoms

2013